文献速递临床试验与 GCP

优化线性消融联合肺静脉隔离与单纯肺静脉隔离治疗持续性房颤:PROMPT-AF随机临床试验

Pulmonary Vein Isolation With Optimized Linear Ablation vs Pulmonary Vein Isolation Alone for Persistent AF: The PROMPT-AF Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01

PROMPT-AF多中心开放标签随机试验纳入498例持续性房颤患者,比较单纯肺静脉隔离与肺静脉隔离+马歇尔静脉乙醇灌注+线性消融。12个月时干预组70.7% vs 单纯组61.5%未发生房性心律失常且未用抗心律失常药(HR 0.73,95%CI 0.54-0.99,P=0.045),次要结局无显著差异。

要点

  • 持续性房颤单纯肺静脉隔离成功率有限,附加线性消融联合马歇尔静脉乙醇灌注可能改善疗效。
  • 12个月无房性心律失常且未用抗心律失常药:干预组70.7% vs 单纯组61.5%(HR 0.73,95%CI 0.54-0.99,P=0.045)。
  • 次要结局比较未显示显著结果。

核心结论

  • 在持续性房颤患者中,肺静脉隔离基础上联合马歇尔静脉乙醇灌注和线性消融,较单纯肺静脉隔离显著改善12个月内无房性心律失常的维持。

研究设计与样本

  • PROMPT-AF为研究者发起的多中心开放标签随机试验,涉及中国12家三级医院。
  • 2021年8月27日至2023年7月16日纳入498例18至80岁、房颤持续超过3个月、首次接受房颤消融的患者。
  • 患者随机接受单纯肺静脉隔离或肺静脉隔离+马歇尔静脉乙醇灌注+线性消融(干预组)。
  • 干预组先接受马歇尔静脉乙醇灌注,随后行肺静脉隔离及左心房顶部、二尖瓣峡部和三尖瓣峡部线性消融。
  • 主要终点为12个月内无任何记录到的持续超过30秒的房性心律失常且未使用抗心律失常药物。

主要发现

  • 498例随机患者中495例(99.4%)纳入主要分析(平均年龄61.1岁[SD 9.7],男性361例[72.9%])。
  • 12个月时,干预组246例中174例(70.7%)vs 单纯组249例中153例(61.5%)无房性心律失常且未用抗心律失常药物(HR 0.73,95%CI 0.54-0.99,P=0.045)。
  • 干预效应在所有预设亚组中一致。
  • 次要结局比较未显示显著结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Success rates of pulmonary vein isolation (PVI) are modest for persistent atrial fibrillation (AF). Additional linear ablation beyond PVI has not been proved superior to PVI alone in randomized trials. Ethanol infusion of the vein of Marshall (EIVOM) facilitates ablation at the mitral isthmus and may lead to improved effectiveness of a linear ablation strategy. OBJECTIVE: To determine whether linear ablation with radiofrequency energy combined with EIVOM added to PVI improves sinus rhythm maintenance compared with PVI alone in patients with persistent AF. DESIGN, SETTING, AND PARTICIPANTS: The PROMPT-AF trial is an investigator-initiated, multicenter, open-label, randomized trial involving 12 tertiary hospitals in China. A total of 498 patients aged 18 to 80 years, with AF persisting for more than 3 months, undergoing first-time AF ablation, were enrolled and randomized from August 27, 2021, to July 16, 2023. INTERVENTIONS: Patients were randomized to undergo PVI alone or PVI plus EIVOM and linear ablation (intervention). The latter group first underwent EIVOM, followed by PVI and linear ablation of the left atrial roof, mitral isthmus, and cavotricuspid isthmus. MAIN OUTCOMES AND MEASURES: The primary end point was freedom from any documented atrial arrhythmias lasting more than 30 seconds, without the use of antiarrhythmic drugs within 12 months. Secondary outcomes included freedom from atrial arrhythmia recurrence, AF, atrial arrhythmia recurrence after multiple procedures, and documented atrial tachycardia or atrial flutter with or without antiarrhythmic drugs; AF burden; and improvement in quality of life. Patients were monitored with wearable single-lead electrocardiographic (ECG) patches, worn for 24 hours a week, supplemented by symptom-triggered ECGs and Holter monitoring. RESULTS: Among 498 randomized patients, 495 (99.4%) were included in the primary analysis (mean age, 61.1 years [SD, 9.7] years, 361 male [72.9%]). After 12 months, 174 of 246 patients (70.7%) assigned to undergo PVI plus EIVOM and linear ablation and 153 of 249 patients (61.5%) assigned to undergo PVI alone remained free from atrial arrhythmias without taking antiarrhythmic drugs (hazard ratio, 0.73; 95% CI, 0.54-0.99, P = .045). The intervention effect was consistent across all prespecified subgroups. The comparison of secondary outcomes did not demonstrate significant results. CONCLUSION: Among patients with persistent AF, linear ablation combined with EIVOM in addition to PVI significantly improved freedom from atrial arrhythmias within 12 months compared with PVI alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04497376.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Sang C, Liu Q, Lai Y, et al. Pulmonary Vein Isolation With Optimized Linear Ablation vs Pulmonary Vein Isolation Alone for Persistent AF: The PROMPT-AF Randomized Clinical Trial. JAMA. 2025. PMID: 39556379. doi:10.1001/jama.2024.24438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。